Picture Fairtec GmbH Worldwide Event Solutions 650x65px
Financing › Details

Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys


Period Period 2019-10-08
  Predecessor Probiodrug–SEVERAL: investment, 201904 private placement €8.2m net €7.65m with 4.1m new shares at €2m led by Claus Christiansen et al.
Organisation Money taker Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
  Group Vivoryon (Group)
Products Product PQ912 (Probiodrug)
  Product 2 phase 2 study
Index term Index term Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG
Person Person Christiansen, Claus (CCBR + Nordic Bioscience Founder + Chairman)
Document Source Vivoryon Therapeutics AG. (10/8/19). "Press Release: Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments [Not for US, et al.]". Halle (Saale).

Record changed: 2020-01-06


Picture [LSUS] – The Business Web Portal 650x65px

More documents for Vivoryon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top